APA (7th ed.) Citation

Konstantinopoulos, P. A., Kim, J. W., Freyer, G., Lee, J. Y., Gaba, L., Grisham, R. N., . . . González-Martín, A. (2025). Primary analysis of EPIK-O/ENGOT-ov61: Alpelisib plus olaparib versus chemotherapy in platinum-resistant or platinum-refractory high-grade serous ovarian cancer without BRCA mutation. Journal of clinical oncology, 43(26), . https://doi.org/10.1200/JCO-25-00225

Chicago Style (17th ed.) Citation

Konstantinopoulos, Panagiotis A., et al. "Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-resistant or Platinum-refractory High-grade Serous Ovarian Cancer Without BRCA Mutation." Journal of Clinical Oncology 43, no. 26 (2025). https://doi.org/10.1200/JCO-25-00225.

MLA (9th ed.) Citation

Konstantinopoulos, Panagiotis A., et al. "Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-resistant or Platinum-refractory High-grade Serous Ovarian Cancer Without BRCA Mutation." Journal of Clinical Oncology, vol. 43, no. 26, 2025, https://doi.org/10.1200/JCO-25-00225.